Sprint Bioscience AB (publ) (STO: SPRINT)

Sprint Bioscience AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	14.72	-0.44	-60.17	-25.08	-42.79	-21.54
Depreciation & Amortization	0.77	0.45	0.62	0.59	0.7	0.74
Asset Writedown & Restructuring Costs	-	-	-	-	-	-0.01
Other Operating Activities	-	-	-	-0.06	1.05	-
Change in Accounts Receivable	-2.25	-2.55	-0.09	-0.1	3.8	-5.38
Change in Accounts Payable	3.96	2.02	0.84	-0.43	0.85	-2.12
Change in Other Net Operating Assets	6.75	23.39	-0.25	-15.04	4.18	0.3
Operating Cash Flow	23.94	22.87	-59.05	-40.12	-32.22	-28
Capital Expenditures	-3.21	-2.45	-	-2.71	-	-0.09
Investment in Securities	-	-	-	-	-	-0.3
Investing Cash Flow	-3.21	-2.45	-	-2.71	-	-0.39
Short-Term Debt Issued	-	-	-	10	10	-
Total Debt Issued	-	-	-	10	10	-
Short-Term Debt Repaid	-	-	-	-	-	-12
Total Debt Repaid	-	-	-	-	-	-12
Net Debt Issued (Repaid)	-	-	-	10	10	-12
Issuance of Common Stock	0.02	0.02	22.41	88.8	48.93	36.24
Other Financing Activities	-0.25	-	-4.51	-12.41	-8.02	-2.16
Financing Cash Flow	-0.23	0.02	17.9	86.39	50.92	22.08
Net Cash Flow	20.5	20.44	-41.15	43.57	18.7	-6.31
Free Cash Flow	20.73	20.42	-59.05	-42.82	-32.22	-28.1
Free Cash Flow Margin	24.04%	39.50%	-71149.40%	-122.26%	-167.87%	-83.10%
Free Cash Flow Per Share	0.30	0.29	-1.40	-1.48	-1.92	-2.50
Cash Interest Paid	0.39	0.39	0.11	0.37	3.9	1.3
Levered Free Cash Flow	14.9	19.99	-36.81	-23.87	-15.17	-20.07
Unlevered Free Cash Flow	14.9	19.99	-36.81	-23.7	-13.02	-19.32
Change in Net Working Capital	-8.41	-22.82	-0.46	5.67	-9.83	7.2

Source: S&P Capital IQ. Standard template. Financial Sources.